TACR1 and glioblastoma: To summarize, the SP analogues tested in this work can be used (taking into account the lipophilicity and receptor affinity of [177Lu]DOTA-SP radiobioconjugates) as biologically active molecules (potential vectors) able to lead the diagnostic or therapeutic radionuclide to NK-1 receptors overexpressing on glioblastoma cells.